Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/31/2025

Nicardipine Titration Protocol for Hypertensive Emergencies

Initial Dosing and Titration Guidelines

  • The American Heart Association recommends initiating nicardipine at 5 mg/h, increasing every 5 minutes by 2.5 mg/h to a maximum of 15 mg/h for hypertensive emergencies 1
  • The initial dosing and titration of nicardipine should start with 5 mg/h as continuous IV infusion, with increments of 2.5 mg/h every 5 minutes until desired blood pressure is reached, with a maximum recommended dose of 15 mg/h 1, 2

Monitoring Requirements and Blood Pressure Reduction Targets

  • Continuous blood pressure monitoring is essential during titration, and for hypertensive emergencies, intensive care unit admission is recommended for continuous monitoring 1, 2
  • The American College of Cardiology recommends reducing systolic BP by no more than 25% within the first hour for patients without compelling conditions, and then aiming for BP of 160/100 mmHg within the next 2-6 hours 1
  • For patients with compelling conditions, such as aortic dissection or severe preeclampsia/eclampsia, the goal is to reduce systolic BP to less than 140 mmHg during the first hour 1

Special Considerations and Side Effects

  • The European Society of Cardiology notes that nicardipine has an onset of action of 5-15 minutes and a duration of action of 30-40 minutes 3, 4
  • The American Heart Association recommends using nicardipine with caution in patients with liver failure, and notes that it is contraindicated in patients with advanced aortic stenosis 1, 2
  • Common side effects of nicardipine include headache and reflex tachycardia, as well as flushing, dizziness, and peripheral edema 3, 4, 5

Pharmacological Properties

  • The American College of Cardiology notes that nicardipine is a dihydropyridine calcium channel blocker with potent vasodilatory effects, and has minimal effects on cardiac conduction compared to non-dihydropyridine calcium channel blockers 5